BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 23690288)

  • 1. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes.
    Townsley DM; Desmond R; Dunbar CE; Young NS
    Int J Hematol; 2013 Jul; 98(1):48-55. PubMed ID: 23690288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biology of thrombopoietin and thrombopoietin receptor agonists.
    Kuter DJ
    Int J Hematol; 2013 Jul; 98(1):10-23. PubMed ID: 23821332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H; Kreuzer KA; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guest editorial: Pathophysiology and management of thrombocytopenia: possible clinical application of TPO receptor agonists.
    Tomiyama Y
    Int J Hematol; 2013 Jul; 98(1):8-9. PubMed ID: 23793996
    [No Abstract]   [Full Text] [Related]  

  • 5. Eltrombopag in chronic hepatitis C.
    Mihăilă RG; Cipăian RC
    World J Gastroenterol; 2014 Sep; 20(35):12517-21. PubMed ID: 25253952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists.
    Pecci A
    Int J Hematol; 2013 Jul; 98(1):34-47. PubMed ID: 23636669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The new thrombopoietic agenda: impact on leukemias and MDS.
    Bussel JB
    Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2014.
    Visconte V; Lindsley RC; Berlyne D
    Leuk Res; 2015 Jan; 39(1):110-3. PubMed ID: 25435026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiology and management of primary immune thrombocytopenia.
    Kashiwagi H; Tomiyama Y
    Int J Hematol; 2013 Jul; 98(1):24-33. PubMed ID: 23702914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
    Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
    N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.
    Rodeghiero F; Carli G
    Ann Hematol; 2017 Sep; 96(9):1421-1434. PubMed ID: 28275823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
    Di Buduo CA; Laurent PA; Zaninetti C; Lordier L; Soprano PM; Ntai A; Barozzi S; La Spada A; Biunno I; Raslova H; Bussel JB; Kaplan DL; Balduini CL; Pecci A; Balduini A
    Elife; 2021 Jun; 10():. PubMed ID: 34059198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
    Fattizzo B; Levati G; Cassin R; Barcellini W
    Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
    Zhang X; Chuai Y; Nie W; Wang A; Dai G
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012035. PubMed ID: 29178132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016.
    Zeidan AM; Battiwalla M; Berlyne D; Winkler T
    Leuk Res; 2017 Feb; 53():8-12. PubMed ID: 27923195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experience.
    Beyar-Katz O; Perry C; On YB; Amit O; Gutwein O; Wolach O; Kedar R; Pikovsky O; Avivi I; Gold R; Ben-Ezra J; Shasha D; Ami RB; Ram R
    Ann Hematol; 2022 Aug; 101(8):1769-1776. PubMed ID: 35731278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction to Acquired and Inherited Bone Marrow Failure.
    Sieff CA
    Hematol Oncol Clin North Am; 2018 Aug; 32(4):569-580. PubMed ID: 30047411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
    Gilreath J; Lo M; Bubalo J
    Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of the absolute immature platelet number reflects marrow production and is not impacted by platelet transfusion.
    Bat T; Leitman SF; Calvo KR; Chauvet D; Dunbar CE
    Transfusion; 2013 Jun; 53(6):1201-4. PubMed ID: 23043309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Change in paradigm in the treatment of pediatric acquired bone marrow failure syndromes in Hungary].
    Kállay K; Csomor J; Ádám E; Bödör C; Kassa C; Simon R; Kovács G; Péter G; Ottóffy G; Bartyik K; Kiss C; Masát P; Réti M; Tóth B; Kriván G
    Orv Hetil; 2018 Oct; 159(42):1710-1719. PubMed ID: 30334483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.